CHMP positive for Stoboclo (denosumab biosimilar) intended for the treatment of osteoporosis in post menopausal women, bone loss in men and treatment of systemic glucocorticoid – Celltrion
On 12 December 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Stoboclo (denosumab… read more.